Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 10/20 | 0.65 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | GOT1 | P17174 | 1/20 | 0.45 |
| ▸ | IGF1R | P08069 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | PLK4 | O00444 | 1/20 | 0.43 |
| ▸ | ICMT | O60725 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23207936 | 0.93 | STING1 (0.59) | STING1EPHX2MTORGOT1IGF1R | |
| SCHEMBL23207917 | 0.89 | STING1 (0.65) | STING1EPHX2MTORGOT1MEN1 | |
| SCHEMBL30195938 | 0.89 | STING1 (0.65) | STING1EPHX2MTORGOT1MEN1 | |
| SCHEMBL23207646 | 0.89 | STING1 (0.59) | STING1EPHX2MTORGOT1IGF1R | |
| SCHEMBL30195890 | 0.89 | STING1 (0.59) | STING1EPHX2MTORGOT1IGF1R | |
| SCHEMBL23167861 | 0.88 | STING1 (0.73) | STING1EPHX2GOT1IGF1RMEN1 | |
| SCHEMBL23207945 | 0.88 | STING1 (0.66) | STING1EPHX2MTORGOT1MEN1 | |
| SCHEMBL30386673 | 0.88 | STING1 (0.72) | STING1EPHX2MTORGOT1MEN1 | |
| SCHEMBL28991332 | 0.88 | STING1 (0.72) | STING1EPHX2MTORGOT1MEN1 | |
| SCHEMBL23207649 | 0.87 | STING1 (0.65) | STING1EPHX2GOT1MAPTGRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002320-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-01-05 | — | — | US | disclosed |
| US-20230002320-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-01-05 | — | — | US | disclosed |
| WO-2021067801-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002320-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | STING1 1/4885EPHX2 730/4885MTOR 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.